New Hepatitis C Treatment Shows Promise

Drug prevented virus from replicating in the livers of primates

By Jennifer Thomas
HealthDay Reporter

Related Encyclopedia • Abscess • Actinomycosis • Acute Myeloid Leukemia (Adult) • Adenocarcinoma of the Lung and Brain Metastases More... Related Healthscout Videos Growing Lungs in the Lab: Medicine's Next Big Thing? From Belly to Breast: Rebuilding After Cancer Shaving off Cancer Fluorescent Medicine for Brain Tumors More... Related Animations • Breast Self-Exam Video • Colon Cancer • Hepatitis More... Related Drug Information • Abilify • Augmentin • Bactroban Cream • Bactroban Ointment More... Related News Articles • Long-Term Statin Use Won't Up Cancer Risk: Study • Smokers Urged to Join Thursday's Great American Smokeout • FDA Advisers Renew Review on Whether to Ban Menthol Cigarettes • British Study Supports Mammograms for Some Women Under 50 More...

THURSDAY, Dec. 3 (HealthDay News) -- A new drug to treat hepatitis C has shown promise in a primate study.

The drug, called SPC3649, uses a new strategy to prevent the hepatitis C virus from replicating. Unlike other antivirals that target the virus itself, the new DNA-based drug targets a small RNA molecule in the liver that hepatitis C needs to replicate, the researchers explained.

Text Continues Below

---

By inhibiting the molecule, SPC3649 reduced hepatitis C virus levels in the liver and in the bloodstream in chimpanzees that received the highest dose by 350-fold.

Importantly, the virus showed no signs of resistance to SPC3649, developed by the Denmark-based company Santaris Pharma A/S. And levels of the virus remained low several months after the chimps had ended treatment, raising the possibility that the medicine would only need to be taken temporarily, the researchers added.

"It is a conceptually new approach. Instead of directly targeting the virus, the drug targeted a liver-specific molecule necessary for replication," said study author Robert Lanford, a scientist at the Southwest Foundation for Biomedical Research in San Antonio, Texas. "If we take that away from the virus, it can't replicate anymore."

Viruses replicate inside cells. Like small factories, they require all of the "machinery" inside the cell to accomplish this, explained Lanford. "The beauty of this drug is it takes away the host factor that the virus needs to replicate, and the virus cannot gain a mutation that allows it to be resistant to it."

The study appears in the Dec. 3 online edition of Science.

Hepatitis C, which is spread by contact with the blood of someone who is infected, infects the liver. About 70 percent to 80 percent of those with the virus have no symptoms initially, according to the U.S. Centers for Disease Control and Prevention. But over time, between 60 percent and 70 percent will develop chronic liver disease. Eventually, the virus can cause enough damage to the liver to lead to the formation of scar tissue, and eventually cirrhosis. The virus can also cause liver cancer.

Page:  1 | 2 | Next >>